Related references
Note: Only part of the references are listed.Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical trials design and treatment tailoring: General principles applied to breast cancer research
P. Therasse et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Drug development in oncology: classical cytotoxics and molecularly targeted agents
Shivaani Kummar et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Bayesian clinical trials
DA Berry
NATURE REVIEWS DRUG DISCOVERY (2006)
Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments
PF Thall et al.
STATISTICS IN MEDICINE (2005)
Randomized phase II designs in cancer clinical trials: Current status and future directions
JJ Lee et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
On the efficiency of targeted clinical trials
A Maitournam et al.
STATISTICS IN MEDICINE (2005)
Introduction to Bayesian methods II: fundamental concepts
TA Louis
CLINICAL TRIALS (2005)
Introduction to Bayesian methods I: measuring the strength of evidence
SN Goodman
CLINICAL TRIALS (2005)
Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis
DA Berry
CLINICAL TRIALS (2005)
Development of molecular targeted anticancer agents: Successes, failures and future directions
EX Chen et al.
CURRENT PHARMACEUTICAL DESIGN (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Bayesian statistics and the efficiency and ethics of clinical trials
DA Berry
STATISTICAL SCIENCE (2004)
Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy
M Wolf et al.
CLINICAL CANCER RESEARCH (2004)
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
JW Park et al.
CLINICAL CANCER RESEARCH (2004)
Evaluating the efficiency of targeted designs for randomized clinical trials
R Simon et al.
CLINICAL CANCER RESEARCH (2004)
Optimality, variability, power: Evaluating response-adaptive randomization procedures for treatment comparisons
FF Hu et al.
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION (2003)
The method of minimization for allocation to clinical trials: a review
NW Scott et al.
CONTROLLED CLINICAL TRIALS (2002)
Ethical issues in oncology biostatistics
PF Thall
STATISTICAL METHODS IN MEDICAL RESEARCH (2002)
Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?
CR Palmer
STATISTICAL METHODS IN MEDICAL RESEARCH (2002)
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
FV Fossella et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
